1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
J-M. Placke(Essen University Hospital), S. Ugurel-Becker(Ruhrlandklinik), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Klaus Griewank(Düsseldorf University Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pfoehler(MSH Medical School Hamburg – University of Applied Sciences and Medical University), Martin Kimmig(Essen University Hospital), P. Terheyden(University Hospital Schleswig-Holstein), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Julia Welzel(University Hospital Augsburg), Alpaslan Tasdogan(Düsseldorf University Hospital), Jürgen C. Becker(Düsseldorf University Hospital), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Eva Hadaschik(West German Heart and Vascular Center Essen), Jens Ulrich, Jochen Utikal(German Cancer Research Center)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k